Randomized Trialhigh evidence
Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD.
Cell metabolism·December 2, 2025·PMID 41270737
Why it mattersIt explains why some patients with MASLD do not respond to resistant starch, identifies a microbial mechanism, and offers a tool to personalize prebiotic therapy, which could improve treatment selection and outcomes in metabolic liver disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled